期刊文献+

细胞色素P450同工酶2C9及维生素K环氧化物还原酶亚单位1基因多态性对华法林用量的影响

下载PDF
导出
摘要 目的探讨细胞色素P450同工酶2C9(CYP2C9)及维生素K环氧化物还原酶亚单位1(VKORC1)基因多态性分布情况及对华法林用量的影响。方法收集2014年3月至2016年10月宁波大学医学院附属医院临床口服华法林患者70例,应用PCR-荧光探针法检测CYP2C9和VKORC1基因多态性,记录患者年龄、体重、身高、凝血酶原时间、国际标准化比值、华法林剂量等指标。结果 VKORC1AA+CYP2C9*1/*1基因型58例(82.9%)、VKORC1AA+CYP2C9*1/*3基因型5例(7.1%)、VKORC1AG+CYP2C9*1/*1基因型5例(7.1%)、VKORC1GG+CYP2C 9*1/*1基因型2例(2.9%),服用华法林平均剂量分别为(3.1±0.5)mg/d、(1.6±0.1)mg/d、(4.4±0.4)mg/d、(5.5±0.4)mg/d。结论患者中CYP2C9和VKORC1基因存在多态性,且不同基因型患者间华法林用量差别较大。
作者 应建波 孙浩
出处 《中国乡村医药》 2018年第18期38-39,共2页
  • 引文网络
  • 相关文献

参考文献2

二级参考文献57

  • 1胡永芳,周宏灏.CYP3A4,CYP3A5和MDR1基因多态性对环孢素处置的影响[J].中国药理学通报,2005,21(3):257-261. 被引量:34
  • 2Aithal GP,Day CP,Keateven PJ,Daly AK.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet 1999; 353:717-719.
  • 3Higashi MK,Veenstra DL,Kondo LM,Wittkowsky AK,Srinouanprachanh SL,Farin FM,et al.Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.JAMA 2002; 287:1690-1698.
  • 4Taube J,Halsall D,Baglin T.Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation on patients on long-term treatment.Blood 2000; 96:1816-1819.
  • 5Kirchheiner J,Brockmoller J.Clinical consequences of cytochrome P450 2C9 polymorphisms.Clin Pharmacol Ther 2005; 77:1-16.
  • 6Rieder MJ,Reiner AP,Gage BF,Nickerson DA,Eby CS,McLeod HL,et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N Engl J Med 2005; 352:2285-2293.
  • 7Montes R,Gaona ER,Martinez-Gonzalez MA,Aoberca I,Hermida J.The c.-1639G >A polymorphism of the VKORC1 gene is a major determinant of the response to acemocoumarol in anticoagulated patients.Br J Haematol.2006; 133:183-187.
  • 8Yuan HY,Chen JJ,Lee MT,Wung JC,Chen YF,Chamg MJ,et al.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum Mol Genet 2005; 14:1745-1751.
  • 9Wadelius M,Chen LY,Dowries K,Ghori J,Hunt S,Eriksson N,et al.Common VKORC1 and GGCX polymorphisms associated with warfarin dose.Pharmacogenomics J 2005; 5:262-270.
  • 10Bodin L,Verstuyft C,Tregouet DA,Robert A,Dubert L,Funck-Brentano C,et al.Cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood 2005; 106:135-140.

共引文献29

;
使用帮助 返回顶部